nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

15.01.2018 | Editorial Commentary

¹⁸F-Fluorocholine PET/CT as a second line nuclear imaging technique before surgery for primary hyperparathyroidism

verfasst von: Alessio Imperiale, David Taïeb, Elif Hindié

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Excerpt

Primary hyperparathyroidism (PHPT) is a common endocrine disorder for which parathyroid surgery is the only curative treatment [1]. It is most commonly seen after the age of 50 years, with three to four times more women than men. PHPT has evolved in its clinical presentation over the past 40 years and is now usually diagnosed at an asymptomatic stage. Guidelines for surgical decision making in asymptomatic patients have been established [1]. …

Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young JE, Rejnmark L, et al. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int. 2017;28:1–19.CrossRefPubMed

Duan K, Gomez Hernandez K, Mete O. Clinicopathological correlates of hyperparathyroidism. J Clin Pathol. 2015;68:771–87.CrossRefPubMed

Phitayakorn R, McHenry CR. Incidence and location of ectopic abnormal parathyroid glands. Am J Surg. 2006;191:418–23.CrossRefPubMed

Thier M, Nordenström E, Bergenfelz A, Almquist M. Presentation and outcomes after surgery for primary hyperparathyroidism during an 18-year period. World J Surg. 2016;40:356–64.CrossRefPubMed

Russell CF, Edis AJ. Surgery for primary hyperparathyroidism: experience with 500 consecutive cases and evaluation of the role of surgery in the asymptomatic patient. Br J Surg. 1982;69:244–7.CrossRefPubMed

Hindié E, Mellière D, Perlemuter L, Jeanguillaume C, Galle P. Primary hyperparathyroidism: higher success rate of first surgery after preoperative Tc-99m sestamibi-I-123 subtraction scanning. Radiology. 1997;204:221–8.CrossRefPubMed

Roy M, Mazeh H, Chen H, Sippel RS. Incidence and localization of ectopic parathyroid adenomas in previously unexplored patients. World J Surg. 2013;37:102–6.CrossRefPubMed

Hindié E, Ugur O, Fuster D, O'Doherty M, Grassetto G, Ureña P, et al. EANM parathyroid guidelines. Eur J Nucl Med Mol Imaging. 2009;36:1201–16.CrossRefPubMed

Westerdahl J, Bergenfelz A. Unilateral versus bilateral neck exploration for primary hyperparathyroidism: five-year follow-up of a randomized controlled trial. Ann Surg. 2007;246:976–80. Discussion 980-1CrossRefPubMed

10.

Guerin C, Lowery A, Gabriel S, Castinetti F, Philippon M, Vaillant-Lombard J, et al. Preoperative imaging for focused parathyroidectomy: making a good strategy even better. Eur J Endocrinol. 2015;172:519–26.CrossRefPubMed

11.

Hindié E, Zanotti-Fregonara P, Tabarin A, Rubello D, Morelec I, Wagner T, et al. The role of radionuclide imaging in the surgical management of primary hyperparathyroidism. J Nucl Med. 2015;56:737–44.CrossRefPubMed

12.

Kluijfhout WP, Pasternak JD, Drake FT, Beninato T, Gosnell JE, Shen WT, et al. Use of PET tracers for parathyroid localization: a systematic review and meta-analysis. Langenbecks Arch Surg. 2016;401:925–35.CrossRefPubMedPubMedCentral

13.

Quak E, Blanchard D, Houdu B, Le Roux Y, Ciappuccini R, Lireux B, et al. F18-choline PET/CT guided surgery in primary hyperparathyroidism when ultrasound and MIBI SPECT/CT are negative or inconclusive: the APACH1 study. Eur J Nucl Med Mol Imaging. 2017. doi:https://doi.org/10.1007/s00259-017-3911-1.PubMed

14.

Elaraj DM, Sippel RS, Lindsay S, Sansano I, Duh QY, Clark OH, et al. Are additional localization studies and referral indicated for patients with primary hyperparathyroidism who have negative sestamibi scan results? Arch Surg. 2010;145:578–81.CrossRefPubMed

15.

Dy BM, Richards ML, Vazquez BJ, Thompson GB, Farley DR, Grant CS. Primary hyperparathyroidism and negative Tc99 sestamibi imaging: to operate or not? Ann Surg Oncol. 2012;19:2272–8.CrossRefPubMed

16.

Wu S, Hwang SS, Haigh PI. Influence of a negative sestamibi scan on the decision for parathyroid operation by the endocrinologist and surgeon. Surgery. 2017;161:35–43.CrossRefPubMed

17.

Ciappuccini R, Morera J, Pascal P, Rame JP, Heutte N, Aide N, et al. Dual-phase 99mTc sestamibi scintigraphy with neck and thorax SPECT/CT in primary hyperparathyroidism: a single-institution experience. Clin Nucl Med. 2012;37:223–8.CrossRefPubMed

18.

Krakauer M, Wieslander B, Myschetzky PS, Lundstrøm A, Bacher T, Sørensen CH, et al. A prospective comparative study of parathyroid dual-phase scintigraphy, dual-isotope subtraction scintigraphy, 4D-CT, and ultrasonography in primary hyperparathyroidism. Clin Nucl Med. 2016;41:93–100.

19.

Schalin-Jäntti C, Ryhänen E, Heiskanen I, Seppänen M, Arola J, Schildt J, et al. Planar scintigraphy with 123I/99mTc-sestamibi, 99mTc-sestamibi SPECT/CT, 11C-methionine PET/CT, or selective venous sampling before reoperation of primary hyperparathyroidism? J Nucl Med. 2013;54:739–47.CrossRefPubMed

20.

Caveny SA, Klingensmith WC 3rd, Martin WE, Sage-El A, McIntyre RC Jr, Raeburn C, et al. Parathyroid imaging: the importance of dual-radiopharmaceutical simultaneous acquisition with 99mTc-sestamibi and 123I. J Nucl Med Technol. 2012;40:104–10.CrossRefPubMed

21.

Hindié E, Mellière D, Jeanguillaume C, Perlemuter L, Chéhadé F, Galle P. Parathyroid imaging using simultaneous double-window recording of technetium-99m-sestamibi and iodine-123. J Nucl Med. 1998;39:1100–5.PubMed

22.

Neumann DR, Obuchowski NA, Difilippo FP. Preoperative 123I/99mTc-sestamibi subtraction SPECT and SPECT/CT in primary hyperparathyroidism. J Nucl Med. 2008;49:2012–7.CrossRefPubMed

23.

Hassler S, Ben-Sellem D, Hubele F, Constantinesco A, Goetz C. Dual-isotope 99mTc-MIBI/123I parathyroid scintigraphy in primary hyperparathyroidism: comparison of subtraction SPECT/CT and pinhole planar scan. Clin Nucl Med. 2014;39:32–6.CrossRefPubMed

24.

Bhatt PR, Klingensmith WC 3rd, Bagrosky BM, Walter JC, McFann KK, McIntyre RC Jr, et al. Parathyroid imaging with simultaneous acquisition of 99mTc-sestamibi and 123I: the relative merits of pinhole collimation and SPECT/CT. J Nucl Med Technol. 2015;43:275–81.CrossRefPubMed

25.

Krishnamurthy VD, Sound S, Okoh AK, Yazici P, Yigitbas H, Neumann D, et al. The utility of repeat sestamibi scans in patients with primary hyperparathyroidism after an initial negative scan. Surgery. 2017;161:1651–8.CrossRefPubMed

26.

Martin D, Rosen IB, Ichise M. Evaluation of single isotope technetium 99m-sestamibi in localization efficiency for hyperparathyroidism. Am J Surg. 1996;172:633–6.CrossRefPubMed

27.

Hughes DT, Miller BS, Park PB, Cohen MS, Doherty GM, Gauger PG. Factors in conversion from minimally invasive parathyroidectomy to bilateral parathyroid exploration for primary hyperparathyroidism. Surgery. 2013;154:1428–34. Discussion 1434-5CrossRefPubMed

28.

Bergenfelz AO, Wallin G, Jansson S, Eriksson H, Mårtensson H, Christiansen P, et al. Results of surgery for sporadic primary hyperparathyroidism in patients with preoperatively negative sestamibi scintigraphy and ultrasound. Langenbecks Arch Surg. 2011;396:83–90.CrossRefPubMed

29.

Michaud L, Balogova S, Burgess A, Ohnona J, Huchet V, Kerrou K, et al. A pilot comparison of 18F-fluorocholine PET/CT, ultrasonography and 123I/99mTc-sestamibi dual-phase dual-isotope scintigraphy in the preoperative localization of hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism: influence of thyroid anomalies. Medicine (Baltimore). 2015;94:e1701.CrossRef

30.

Kluijfhout WP, Pasternak JD, Gosnell JE, Shen WT, Duh QY, Vriens MR, et al. ¹⁸F Fluorocholine PET/MR imaging in patients with primary hyperparathyroidism and inconclusive conventional imaging: a prospective pilot study. Radiology. 2017;284:460–7.CrossRefPubMed

31.

Thanseer N, Bhadada SK, Sood A, Mittal BR, Behera A, Gorla AKR, et al. Comparative effectiveness of ultrasonography, 99mTc-sestamibi, and 18F-fluorocholine PET/CT in detecting parathyroid adenomas in patients with primary hyperparathyroidism. Clin Nucl Med. 2017;42:e491–7.CrossRefPubMed

32.

Lezaic L, Rep S, Sever MJ, Kocjan T, Hocevar M, Fettich J. 18F-Fluorocholine PET/CT for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism: a pilot study. Eur J Nucl Med Mol Imaging. 2014;41:2083–9.CrossRefPubMed

33.

Rep S, Lezaic L, Kocjan T, Pfeifer M, Sever MJ, Simoncic U, et al. Optimal scan time for evaluation of parathyroid adenoma with [(18)F]-fluorocholine PET/CT. Radiol Oncol. 2015;49:327–33.CrossRefPubMedPubMedCentral

34.

Battini S, Imperiale A, Taïeb D, Elbayed K, Cicek AE, Sebag F, et al. High-resolution magic angle spinning (1)H nuclear magnetic resonance spectroscopy metabolomics of hyperfunctioning parathyroid glands. Surgery. 2016;160:384–94.CrossRefPubMed

35.

Calabria F, Chiaravalloti A, Schillaci O. (18)F-choline PET/CT pitfalls in image interpretation: an update on 300 examined patients with prostate cancer. Clin Nucl Med. 2014;39:122–30.PubMed

Titel: 18F-Fluorocholine PET/CT as a second line nuclear imaging technique before surgery for primary hyperparathyroidism
verfasst von: Alessio Imperiale
David Taïeb
Elif Hindié
Publikationsdatum: 15.01.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 4/2018
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-017-3920-0

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

Correction to: Diagnostic and prognostic value of baseline FDG PET/CT skeletal textural features in diffuse large B cell lymphoma

Isam Alobid and Paolo Castelnuovo (editors): Nasoseptal Perforations: Endoscopic Repair Techniques

[68Ga]Pentixafor-PET/MRI for the detection of Chemokine receptor 4 expression in atherosclerotic plaques

Tumour functional sphericity from PET images: prognostic value in NSCLC and impact of delineation method

Impact of improved attenuation correction featuring a bone atlas and truncation correction on PET quantification in whole-body PET/MR

Up-front PET/CT changes treatment intent in patients with head and neck squamous cell carcinoma